GASPING FOR DOCTORS’ ATTENTION

Liquidia | Market Shaping

Liquidia was preparing to launch a new formulation of treprostinil that represents a huge benefit to patients with PH-ILD, or pulmonary hypertension associated with interstitial lung disease. Unfortunately, patients with PH-ILD are often assessed after they have seen significant functional decline.

A serious-looking middle-aged man stands beside text reading, Unexplained dyspnea may be a sign of something worse. Could PH be lurking behind his ILD? Jim has stable PFTs but rising Dyspnea-12 scores—an issue medtech marketing must address for better outcomes.
Infographic about PH-ILD shows poor outcomes: 35% three-year survival rate without intervention, all PH severity linked to reduced survival, and worse transplant outcomes if uncontrolled. Ideal for healthcare marketing or medtech marketing efforts. Photos included.

Opportunity

Discerning PH from the underlying lung disease can be difficult, because both conditions result in reduced lung function. However, dyspnea, or difficulty breathing, tends to worsen to a greater degree when PH is difficult.

outcome

By bringing worsening dyspnea to life and enabling community pulmonologists with practical assessment tools, Liqudia was able to help providers get more patients assessed for PH-ILD and prepare for their new launch.

A middle-aged man with gray hair and a neutral expression stands before a light blue background. Text beside him highlights tracking worsening shortness of breath with the DYSPNEA-12 questionnaire for effective pharma marketing strategies.
A healthcare professional consults an older woman indoors. The image outlines signs and tests for ILD patients with worsening dyspnea, offering insights valuable for pharma marketing or medtech marketing teams shaping diagnostic strategies.

view more case studies

 Back to top